Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib sequential adjuvant therapy after trastuzumab + pertuzumab in non-pCR HER2-positive breast cancer
ChiCTR2100048136Phase 3Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pyrotinib, trastuzumab and pertuzumab in breast cancer (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Invasive disease-free survival. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100048136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048136.